How big is Evoke Pharma, Inc.?

As of Jun 18, Evoke Pharma, Inc. has a market capitalization of 4.14 million, categorizing it as a Micro Cap company, with net sales of 11.59 million and a net profit of -5.08 million for the latest four quarters ending in March 2025. As of December 2024, the company's shareholder's funds were 7.04 million, and total assets were 17.52 million.

Market Cap: As of Jun 18, Evoke Pharma, Inc. has a market capitalization of 4.14 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters ending in March 2025, Evoke Pharma reported net sales of 11.59 million. During the same period, the company experienced a net profit of -5.08 million.<BR><BR>Balance Sheet Snapshot: As of December 2024, Evoke Pharma's shareholder's funds amounted to 7.04 million, while total assets were reported at 17.52 million.

What does Evoke Pharma, Inc. do?

Evoke Pharma, Inc. is a micro-cap specialty pharmaceutical company focused on developing treatments for gastrointestinal disorders. As of March 2025, it reported net sales of $3 million and a net loss of $1 million, with a market cap of $4.14 million.

Overview:<BR>Evoke Pharma, Inc. is a specialty pharmaceutical company focused on developing drugs to treat gastrointestinal disorders and diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 3 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -1 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 4.14 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.29 <BR>Return on Equity: -86.94% <BR>Price to Book: 0.71<BR><BR>Contact Details:<BR>Address: 420 Stevens Ave Ste 370, SOLANA BEACH CA: 92075-2081 <BR>Tel: 1 858 3451494 <BR>Fax: 1 302 6365454 <BR>Website: https://evokepharma.com/

Should I buy, sell or hold Evoke Pharma, Inc.?

Who are in the management team of Evoke Pharma, Inc.?

As of March 2022, the management team of Evoke Pharma, Inc. includes Chairman and Co-Founder Cam Garner, CEO and Founder David Gonyer, and Directors Todd Brady, Ann Rhoads, and Ken Widder.

As of March 2022, the management team of Evoke Pharma, Inc. includes the following individuals:<BR><BR>- Mr. Cam Garner, who serves as the Chairman and Co-Founder.<BR>- Mr. David Gonyer, who is the CEO, Founder, and a Director.<BR>- Dr. Todd Brady, who is a Director.<BR>- Ms. Ann Rhoads, who is also a Director.<BR>- Dr. Ken Widder, who serves as a Director.

Is Evoke Pharma, Inc. overvalued or undervalued?

As of November 10, 2021, Evoke Pharma, Inc. is considered risky and overvalued based on its financial metrics, with key ratios indicating significant valuation concerns and underperformance compared to peers and the S&P 500.

As of 10 November 2021, Evoke Pharma, Inc. has moved from a grade of does not qualify to risky. The company is currently overvalued given its financial metrics and peer comparisons. Key ratios include a Price to Book Value of 0.75, an EV to EBIT of 0.63, and an EV to EBITDA of 0.63, which indicate significant valuation concerns relative to its earnings and assets.<BR><BR>In comparison with its peers, Evoke Pharma's EV to EBITDA ratio of -0.2076 is notably worse than Agile Therapeutics, Inc. at -0.5982 and Bellerophon Therapeutics, Inc. at 0.4464, highlighting its underperformance in generating earnings relative to its enterprise value. Additionally, while the company has shown a YTD return of 14.93%, it has significantly lagged behind the S&P 500's 12.22% return, and its long-term performance is concerning with a 5Y return of -99.28%.

Is Evoke Pharma, Inc. technically bullish or bearish?

As of September 2, 2025, Evoke Pharma, Inc. shows a mildly bullish trend despite mixed signals, with a bullish MACD and moving averages, but a bearish weekly RSI and underperformance against the S&P 500 in the short term.

As of 2 September 2025, the technical trend for Evoke Pharma, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by a bullish MACD on the weekly timeframe and mildly bullish signals from both the Bollinger Bands and moving averages on the daily timeframe. However, the weekly RSI is bearish, and the Dow Theory indicates a mildly bearish trend. <BR><BR>In terms of performance, the stock has underperformed the S&P 500 over the past week and month, with returns of -1.93% and -14.77% respectively, while it has outperformed on a year-to-date and one-year basis with returns of 14.93% and 19.81%. Overall, the mixed signals suggest caution despite the mildly bullish trend.